1. Home
  2. ALRN
Logo Aileron Therapeutics Inc.

ALRN

Aileron Therapeutics Inc.

as 07-26-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
Founded: 2001 Country:
United States
United States
Employees: N/A City: AUSTIN
Market Cap: 64.6M IPO Year: 2017
Target Price: $19.00 AVG Volume (30 days): 69.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.22 EPS Growth: N/A
52 Week Low/High: $1.01 - $7.42 Next Earning Date: 08-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ALRN Daily Stock ML Predictions

ALRN Forecast & Prediction

Stock Insider Trading Activity of Aileron Therapeutics Inc. (ALRN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 14 '24 Sell $3.30 1,900 $6,270.00 1,751,256 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 14 '24 Sell $3.25 4,707 $15,297.75 1,746,549 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 10 '24 Sell $3.30 9,577 $31,604.10 1,768,250 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 10 '24 Sell $3.25 5,250 $17,062.50 1,763,000 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 10 '24 Sell $3.35 502 $1,681.70 1,762,498 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 10 '24 Sell $3.25 9,341 $30,358.25 1,753,157 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 10 '24 Sell $3.28 1 $3.28 1,753,156 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 5 '24 Sell $3.30 6,291 $20,760.30 1,783,851 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 5 '24 Sell $3.27 1,100 $3,597.00 1,782,751 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 5 '24 Sell $3.30 3,184 $10,507.20 1,779,567 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 5 '24 Sell $3.25 1,564 $5,083.00 1,778,003 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner Jun 5 '24 Sell $3.30 176 $580.80 1,777,827 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.92 6,680 $32,865.60 1,803,777 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.93 274 $1,350.82 1,803,503 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.94 100 $494.00 1,803,403 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $5.00 3,231 $16,155.00 1,800,172 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $5.01 13 $65.07 1,800,159 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $5.03 448 $2,251.20 1,799,711 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.95 45 $222.75 1,799,666 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $5.00 45 $225.00 1,799,621 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.10 3,100 $12,710.00 1,796,521 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.11 100 $411.00 1,796,421 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.12 1,750 $7,210.00 1,794,671 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.13 380 $1,569.40 1,794,291 SEC Form 4
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO ALRN 10% Owner May 1 '24 Sell $4.15 1,600 $6,632.00 1,792,691 SEC Form 4

Latest Aileron Therapeutics Inc. News

ALRN Breaking Stock News: Dive into ALRN Ticker-Specific Updates for Smart Investing

Aileron Therapeutics to be Included in the Russell Microcap® Index

PR Newswire

a month ago

Aileron Therapeutics to be Included in the Russell Microcap® Index

Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

2 months ago

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

Zacks

3 months ago

Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire

3 months ago

Aileron Therapeutics to Present at Two Upcoming Investor Conferences

MT Newswires

3 months ago

Aileron Therapeutics Closes Direct Offering of Shares, Warrants

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

GlobeNewswire

3 months ago

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Aileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trial

Clinical Trials Arena

3 months ago

Aileron reports data from Cohort 1 of Phase Ib inhaled IPF treatment trial

All ALRN News

Compare ALRN vs Leading Stocks

ALRN VS BEAT

ALRN VS KPLT

ALRN VS IHTA

ALRN VS YTRA

ALRN VS TOPS

ALRN VS SLS

ALRN VS REE

ALRN VS SHOT

Share on Social Networks:

Similar to ALRN Stocks: